Type 1 interferonopathy
MONDO:0700264Conditions in which increased type 1 interferon signaling leads to autoimmune and neurological disorders. These disorders are caused by variants in genes involved in nucleic acid metabolism, sensing, and the innate immune response.
31 clinical trials for this condition and its sub-types, 4 tagged with Type 1 interferonopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Type 1 interferonopathy
-
Type 1 interferonopathy of childhood 0 trials · 19 incl. sub-types
12 sub-types
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Autoimmune interstitial lung disease-arthritis syndrome 3 trials Sub-types →
- Deficiency of adenosine deaminase 2 3 trials
- Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations 3 trials
- STING-associated vasculopathy with onset in infancy 2 trials
- Familial chilblain lupus 2 trials Sub-types →
- Proteosome-associated autoinflammatory syndrome 2 trials Sub-types →
- Singleton-Merten dysplasia 1 trial Sub-types →
- Spondyloenchondrodysplasia with immune dysregulation 0 trials
- X-linked reticulate pigmentary disorder 0 trials
- Pseudo-TORCH syndrome 2 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
TREX1-related type 1 interferonopathy 0 trials · 5 incl. sub-types
3 sub-types
-
ADAR-related type 1 interferonopathy 0 trials · 1 incl. sub-types
2 sub-types
- Dyschromatosis symmetrica hereditaria 1 trial
- Aicardi-Goutieres syndrome 6 0 trials
-
2 sub-types
- Aicardi-Goutieres syndrome 7 0 trials
- Singleton-Merten syndrome 1 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 4 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 2 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 3 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 9 0 trials
-
2 sub-types
- Aicardi-Goutieres syndrome 5 0 trials
- Chilblain lupus 2 0 trials
Most studied deeper sub-types
-
New drug hope for rare childhood immune disorders
Disease control Recruiting nowThis early-stage trial tests a new medicine called IMSB301 in people with rare diseases where the immune system attacks the body. The study includes up to 6 participants aged 12 and older. The main goal is to check if the drug is safe and how it behaves in the body.
Phase 1 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
500-Patient study aims to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 500 children and adults with rare genetic disorders called type I interferonopathies, which cause severe inflammation and neurological problems. Researchers will track how the disease progresses over time and look for biological markers to improve diagnosis and…
Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists hunt for genetic clues in rare childhood immune disorders
Knowledge-focused Recruiting nowThis study is not a treatment trial. It aims to collect blood samples from 400 children and their relatives who have rare autoimmune or autoinflammatory diseases (like lupus or juvenile arthritis). Researchers will analyze the samples to find genetic mutations that cause these co…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC